Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína2. fázis

A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo

A legfontosabb adatok

Ki végzi
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Hol
Shenyang (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
200 fő, tervezett
Kezdés
2025. nov. 5.
Várható befejezés
2026. dec. 31.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • QY201 Tablets(5mg)
  • QY201 Tablets(10mg)
  • QY201 Tablets(20mg)
  • QY201 Placebo Tablets
A regiszteradat frissítve
2026. július 17.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with non-segmental vitiligo, a condition where patches of skin lose their color. It tests QY201 tablets against placebo.

Életkor
18 to 65 years
Nem
All sexes
A betegség stádiuma
Non-segmental vitiligo that is either spreading (active) or stable. Face score F-VASI ≥ 0.5 and total body score T-VASI ≥ 5 at screening and baseline.
Korábbi kezelés
No small-molecule targeted drugs or biological drugs within 12 weeks before the start. No light therapy, laser or indoor tanning within 12 weeks. No systemic immune drugs, Chinese herbal medicines or other vitiligo pills within 4 weeks. No skin creams for vitiligo within 2 weeks. Never had permanent skin-lightening treatment or vitiligo surgery.
Biomarker vagy leletérték
Women who can become pregnant need a negative blood pregnancy (HCG) test at screening.

A részvétel fő kizáró okai

  • Pregnant or breastfeeding, or unwilling to use effective birth control until 3 months after the last dose
  • Past permanent depigmentation therapy (such as monobenzone, phenol) or vitiligo surgery such as MKTP
  • Long-acting blood thinners within 4 weeks or needing ongoing blood thinners (aspirin ≤100 mg per day is allowed)
  • Strong CYP3A inhibitors or inducers within 2 weeks, or live vaccines planned around or during the study
  • Another drug trial within 4 weeks or a device trial within 3 months before baseline

A regiszter feltételei, szó szerint

Mind a 15 feltétel megnézéseKevesebb

Ki vehet részt

  • The subject is able to communicate well with investigators, fully understands the purpose, nature, methods and potential adverse reactions of this trial, voluntarily participates as a study subject, comprehends and complies with all requirements of this research, and signs the Informed Consent Form (ICF) prior to initiation of any study procedures
  • At the time of ICF signature, the subject is aged ≥18 and ≤65 years old, with no restriction on gender
  • Clinically diagnosed with non-segmental vitiligo at screening
  • Subjects must meet the following criteria at screening and baseline:; F-VASI ≥ 0.5 and T-VASI ≥ 5 at both screening and baseline; The disease is in progressive (active) phase or stable phase at screening and baseline; Progressive vitiligo: defined as appearance of new lesions or enlargement of existing lesions within the past 6 months (confirmed by photographs or medical records), or presence of confetti lesions, trichrome lesions, or Koebner phenomenon; Stable vitiligo: defined as absence of any signs of disease activity
  • The subject (and partner if applicable) agrees to avoid pregnancy and adopt effective contraceptive measures from ICF signature through 3 months after the last study drug administration; Male subjects: must commit not to donate sperm during the study period and within 3 months after the last study medication; Female subjects:; Women of childbearing potential: have a negative serum human chorionic gonadotropin (HCG) test at screening and are not breastfeeding; Women without childbearing potential: have undergone permanent sterilization (e.g., bilateral oophorectomy, bilateral salpingectomy, hysterectomy), or are postmenopausal (defined as amenorrhea for more than 12 months excluding other pathological causes of amenorrhea; subjects under 60 years old must have serum follicle-stimulating hormone (FSH) > 40 IU/L)

Ki nem vehet részt

  • Received any of the following treatments within 12 weeks prior to baseline (or 5 half-lives, whichever is longer):; Small-molecule targeted drugs; Macromolecular biological agents
  • Received phototherapy (e.g., ultraviolet B [UVB], psoralen plus ultraviolet A [PUVA], excimer laser or other laser modalities, etc.) including indoor tanning within 12 weeks prior to baseline
  • Received any of the following systemic therapies within 4 weeks prior to baseline (or 5 half-lives, whichever is longer):; Systemic immunosuppressive or immunomodulatory drugs; Systemic Chinese herbal medicines or proprietary Chinese medicines; Other systemic medications indicated for vitiligo treatment
  • Received any of the following topical treatments within 2 weeks prior to baseline:; Topical corticosteroids (TCS); Topical calcineurin inhibitors (TCI); Topical phosphodiesterase 4 (PDE-4) inhibitors; Topical vitamin D3 analogues; Topical Chinese herbal preparations or herbal bathing for external use; Other topical drugs for vitiligo management
  • Has a history of permanent depigmentation therapy (e.g., monobenzone, phenol) for vitiligo and/or other pigmentary disorders at any time prior to screening
  • Taken strong inhibitors or strong inducers of cytochrome P450 3A (CYP3A) hepatic metabolic enzymes within 2 weeks prior to baseline
  • Received long-acting anticoagulants (e.g., warfarin, clopidogrel, etc.) within 4 weeks prior to baseline, or requires continuous anticoagulant therapy (excluding aspirin at a dose ≤100 mg per day)
  • Planned to receive live or attenuated live vaccines within 4 weeks prior to baseline; or expects to receive live or attenuated live vaccines during the study period (including at least 4 weeks after the last dose of investigational product)
  • Has participated in any clinical trial involving an investigational drug within 4 weeks prior to baseline (or 5 half-lives, whichever is longer), or any clinical trial with an investigational medical device within 3 months prior to baseline
  • Has a history of melanocyte-keratinocyte transplantation procedure (MKTP) or other surgical interventions for vitiligo

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 65 év között vagy?

Helyszínek itt: Kína

  • The First Hospital of China Medical UniversityShenyang, KínaContact: Li QiangRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

To evaluate the efficacy of QY201 Tablets in adult subjects with non-segmental vitiligo, and to provide evidence for dose selection in the confirmatory Phase III clinical trial.

A vizsgálat 4 csoportja

  • QY201 Tablets(5mg)A vizsgált kezelés

    One tablet twice daily for 168 consecutive days

  • QY201 Tablets(10mg)A vizsgált kezelés

    One tablet twice daily for 168 consecutive days

  • QY201 Tablets(20mg)A vizsgált kezelés

    One tablet twice daily for 168 consecutive days

  • QY201 Placebo TabletsPlacebo, összehasonlításként

    One tablet twice daily for 168 consecutive days

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT07712523: ki vehet részt
A regiszteradat frissítve
2026. július 17.